PDCD1 and cancer: Immune checkpoint inhibitors (ICIs) are cancer therapies that activate the host immune response by blocking immune suppressive signaling pathways, such as cytotoxic T-lymphocyte antigen (CTLA-4), programmed cell death 1 (PD-1), and ligand (1).